graph Evidence gap map comparisons
durvalumab based treatment
durvalumab alone
laNSCLC - M - all population 1   
laNSCLC - M - EGFR mutant
Comparator:  vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;